{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T09:27:26Z","timestamp":1786613246122,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"EU","doi-asserted-by":"publisher","award":["I83C22001810007"],"award-info":[{"award-number":["I83C22001810007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"award":["I83C22001810007"],"award-info":[{"award-number":["I83C22001810007"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab, a long-acting monoclonal antibody, provides single-dose protection during the RSV season, but the effectiveness of prophylaxis programs depends on sustained parental acceptance and high uptake. This study evaluated changes in parental knowledge, perceptions, and willingness to accept nirsevimab across two consecutive RSV seasons in Emilia-Romagna, Italy. Methods: Two multicenter cross-sectional surveys were conducted during consecutive RSV seasons, 2024\u20132025 and 2025\u20132026, using a comparable questionnaire and recruitment approach. Parents or legal guardians of infants eligible for nirsevimab completed a semi-structured questionnaire during routine counseling in neonatal units. Survey 1 included 1042 respondents and survey 2 included 867 respondents. Sociodemographic characteristics, RSV awareness, knowledge and perception of nirsevimab, willingness to accept prophylaxis, trust in healthcare providers and the healthcare system, preferred information sources, and willingness to pay were compared between seasons. Results: Willingness to administer nirsevimab remained high and stable\u201487.04% in survey 1 and 88.00% in survey 2. Awareness of RSV-related risks increased from 68.23% to 73.47% (p &lt; 0.05), and correct identification of nirsevimab as an antibody increased from 65.93% to 71.74% (p &lt; 0.01). Explicit refusal rose slightly from 2.21% to 3.81% (p &lt; 0.05). In survey 2, acceptance was associated with higher education, awareness of RSV risks, perceived child susceptibility, confidence in efficacy, lower concern about side effects, trust in pediatricians and the healthcare system, and willingness to pay. Notably, acceptance in 2025\u20132026 was higher among infants born in September\u2013December than among those born in January\u2013March, indicating a late-season decline. Conclusions: Parental acceptance of nirsevimab remained high across two seasons. Future campaigns should address residual knowledge gaps, reinforce communication on safety and efficacy, and sustain high coverage throughout the entire RSV season, particularly among infants born in its final months.<\/jats:p>","DOI":"10.3390\/vaccines14080696","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:45:06Z","timestamp":1786545906000},"page":"696","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4103-2837","authenticated-orcid":false,"given":"Susanna","family":"Esposito","sequence":"first","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-7484","authenticated-orcid":false,"given":"Valentina","family":"Fainardi","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0848-5228","authenticated-orcid":false,"given":"Maria Elena","family":"Capra","sequence":"additional","affiliation":[{"name":"Pediatrics and Neonatology Unit, Department of Medicine and Surgery, Guglielmo da Saliceto Hospital, University of Parma, 29100 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2072-3559","authenticated-orcid":false,"given":"Melodie O.","family":"Aric\u00f2","sequence":"additional","affiliation":[{"name":"Pediatric Unit, G.B. Morgagni-L. Pierantoni Hospital, AUSL Romagna, 47100 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lanzoni","sequence":"additional","affiliation":[{"name":"Pediatric Unit, Santa Maria della Scaletta Hospital, 40026 Imola, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-106X","authenticated-orcid":false,"given":"Francesco","family":"Accomando","sequence":"additional","affiliation":[{"name":"Pediatric Unit, G.B. Morgagni-L. Pierantoni Hospital, AUSL Romagna, 47100 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia Giorgia","family":"Arnesano","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Neglia","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5735-1949","authenticated-orcid":false,"given":"Enrico","family":"Valletta","sequence":"additional","affiliation":[{"name":"Pediatric Unit, G.B. Morgagni-L. Pierantoni Hospital, AUSL Romagna, 47100 Forl\u00ec, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7441-9248","authenticated-orcid":false,"given":"Giacomo","family":"Biasucci","sequence":"additional","affiliation":[{"name":"Pediatrics and Neonatology Unit, Department of Medicine and Surgery, Guglielmo da Saliceto Hospital, University of Parma, 29100 Piacenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5478-5657","authenticated-orcid":false,"given":"Serafina","family":"Perrone","sequence":"additional","affiliation":[{"name":"Neonatology Unit, University Hospital of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4565","DOI":"10.21037\/jtd-2024-2170","article-title":"Risk factors for respiratory syncytial virus (RSV) infection in children under 5 years old with acute lower respiratory tract infection","volume":"17","author":"Srisingh","year":"2025","journal-title":"J. Thorac. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/QCO.0000000000000952","article-title":"The disease burden of respiratory syncytial virus in Infants","volume":"36","author":"Munro","year":"2023","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-2600(22)00414-3","article-title":"The burden of respiratory syncytial virus in healthy term-born infants in Europe: A prospective birth cohort study","volume":"11","author":"Wildenbeest","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Principi, N., Perrone, S., and Esposito, S. (2025). Challenges and Limitations of Current RSV Prevention Strategies in Infants and Young Children: A Narrative Review. Vaccines, 13.","DOI":"10.3390\/vaccines13070717"},{"key":"ref_5","unstructured":"European Medicines Agency (2026, July 07). Beyfortus. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/beyfortusepar-medicine-overview_en.pdf."},{"key":"ref_6","unstructured":"European Medicines Agency (2026, July 07). New Medicine to Protect Babies and Infants from Respiratory Syncytial Virus Infection. Available online: https:\/\/www.ema.europa.eu\/en\/news\/new-medicine-protect-babies-and-infants-respiratory-syncytial-virus-rsv-infection."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa2309189","article-title":"Nirsevimab for prevention of hospitalizations due to RSV in infants","volume":"389","author":"Drysdale","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1473-3099(25)00742-X","article-title":"Impact of universal nirsevimab prophylaxis in infants on hospital and primary care outcomes across two respiratory syncytial virus seasons in Galicia, Spain (NIRSE-GAL): A population-based prospective observational study","volume":"26","author":"Razzini","year":"2026","journal-title":"Lancet Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101007","DOI":"10.1016\/j.lanepe.2024.101007","article-title":"Effectiveness of nirsevimab against RSV-bronchiolitis in paediatric ambulatory care: A test-negative case-control study","volume":"44","author":"Lassoued","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/S1473-3099(25)00233-6","article-title":"Effectiveness and impact of nirsevimab in Chile during the first season of a national immunisation strategy against RSV (NIRSE-CL): A retrospective observational study","volume":"25","author":"Torres","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Consolati, A., Farinelli, M., Serravalle, P., Rollandin, C., Apprato, L., Esposito, S., and Bongiorno, S. (2024). Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d\u2019Aosta Region, Italy, in the 2023\u20132024 Epidemic Season. Vaccines, 12.","DOI":"10.3390\/vaccines12050549"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1001\/jamapediatrics.2026.0657","article-title":"Nirsevimab Immunization to Prevent Pediatric RSV Hospitalizations","volume":"180","author":"Attaianese","year":"2026","journal-title":"JAMA Pediatr."},{"key":"ref_13","unstructured":"Regione Emilia-Romagna (2026, July 07). Sanit\u00e0, Avviata la Campagna Regionale di Immunizzazione Contro il Virus Respiratorio Sinciziale (VRS). Available online: https:\/\/www.regione.emilia-romagna.it\/notizie\/2025\/settembre\/immunizzazione-vrs."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103281","DOI":"10.1016\/j.eclinm.2025.103281","article-title":"Real-world uptake of nirsevimab, RSV maternal vaccine, and RSV vaccines for older adults: A systematic review and meta-analysis","volume":"84","author":"Trusinska","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e2025070790","DOI":"10.1542\/peds.2025-070790","article-title":"Disparities in Nirsevimab Uptake Across a Pediatric Primary Care Network","volume":"156","author":"Ahmed","year":"2025","journal-title":"Pediatrics"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lipsett, B.J., Fogel, B.N., Shedlock, K.E., Paul, I.M., Schaefer, E.W., Gardner, R.E., Kaye, L.D., and Hicks, S.D. (2025). Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis. Pediatr. Rep., 17.","DOI":"10.3390\/pediatric17050109"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2165","DOI":"10.1016\/S2214-109X(25)00379-1","article-title":"The path to equitable respiratory syncytial virus prevention for infants: Challenges and opportunities for global implementation","volume":"13","author":"Shaaban","year":"2025","journal-title":"Lancet Glob. Health"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Esposito, S., Fainardi, V., Capra, M.E., Aric\u00f2, M., Lanzoni, A., Campana, B.R., Niceforo, M., Neglia, C., Valletta, E., and Biasucci, G. (2025). Acceptance of nirsevimab for the prevention of respiratory syncytial virus infection in neonates: A cross-sectional survey in Emilia-Romagna, Italy. Vaccines, 13.","DOI":"10.3390\/vaccines13090896"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102986","DOI":"10.1016\/j.eclinm.2024.102986","article-title":"Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: A prospective longitudinal cohort study in France","volume":"79","author":"Testard","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1016\/S1473-3099(24)00811-9","article-title":"NIRSE-GAL Study Group. Full 2023\u201324 season results of universal prophylaxis with nirsevimab in Galicia, Spain: The NIRSE-GAL study","volume":"25","author":"Mallah","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1473-3099(24)00215-9","article-title":"Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: Initial results of a population-based longitudinal study","volume":"24","author":"Mallah","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e2520440","DOI":"10.1001\/jamanetworkopen.2025.20440","article-title":"Nirsevimab uptake in a pediatric primary care network during the 2023\u20132024 RSV season","volume":"8","author":"Hossain","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_23","unstructured":"Centers for Disease Control and Prevention (2026, July 07). Pediatrician and Obstetrician\/Gynecologist Survey on RSV Immunization. RSVVaxView, Available online: https:\/\/www.cdc.gov\/rsvvaxview\/publications\/rsv-immunization-survey-2024.html."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00431-025-06588-6","article-title":"Public health impact of nirsevimab and reduction of RSV hospitalisation in all infants: Early real-world data from Tuscany (Italy) in the 2024\u201325 RSV season","volume":"184","author":"Nieddu","year":"2025","journal-title":"Eur. J. Pediatr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(22)00478-0","article-title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: A systematic analysis","volume":"399","author":"Li","year":"2022","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2588016","DOI":"10.1080\/21645515.2025.2588016","article-title":"Parental acceptability of new RSV preventive therapies for infants: A cross-sectional survey in Canada","volume":"22","author":"Fitzpatrick","year":"2026","journal-title":"Hum. Vaccin Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e2024067532","DOI":"10.1542\/peds.2024-067532","article-title":"Parent perspectives on nirsevimab for their newborn","volume":"154","author":"Hinderstein","year":"2024","journal-title":"Pediatrics"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cmi.2016.11.007","article-title":"Addressing vaccine hesitancy: The crucial role of healthcare providers","volume":"23","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1056\/NEJMoa2110275","article-title":"Nirsevimab for prevention of RSV in healthy late-preterm and term infants","volume":"386","author":"Hammitt","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/QCO.0000000000000917","article-title":"Respiratory syncytial virus infection in the modern era","volume":"36","author":"Ludlow","year":"2023","journal-title":"Curr. Opin. Infect. Dis."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/696\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T08:39:47Z","timestamp":1786610387000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/8\/696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":30,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["vaccines14080696"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14080696","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}